Equities Analysts Set Expectations for TVTX FY2028 Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Wedbush decreased their FY2028 earnings per share (EPS) estimates for shares of Travere Therapeutics in a research note issued to investors on Thursday, January 23rd. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of $3.79 for the year, down from their previous forecast of $3.91. Wedbush currently has a “Outperform” rating and a $25.00 target price on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.92) per share.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.01. The business had revenue of $62.90 million for the quarter, compared to the consensus estimate of $60.87 million. Travere Therapeutics had a negative return on equity of 537.74% and a negative net margin of 172.75%. Travere Therapeutics’s revenue for the quarter was up 69.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.17) earnings per share.

Several other research firms have also weighed in on TVTX. Cantor Fitzgerald began coverage on Travere Therapeutics in a report on Friday, January 10th. They set an “overweight” rating on the stock. Piper Sandler boosted their target price on Travere Therapeutics from $12.00 to $22.00 and gave the stock a “neutral” rating in a report on Thursday, November 14th. Guggenheim boosted their price objective on shares of Travere Therapeutics from $23.00 to $41.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. Bank of America raised their target price on shares of Travere Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, October 9th. Finally, Canaccord Genuity Group decreased their price target on shares of Travere Therapeutics from $23.00 to $22.00 and set a “buy” rating for the company in a report on Monday, September 30th. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, Travere Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

Travere Therapeutics Trading Up 6.9 %

NASDAQ:TVTX opened at $20.81 on Friday. The stock’s 50 day moving average price is $18.28 and its 200 day moving average price is $14.79. Travere Therapeutics has a 52 week low of $5.12 and a 52 week high of $20.89. The company has a market capitalization of $1.62 billion, a P/E ratio of -4.57 and a beta of 0.70. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71.

Hedge Funds Weigh In On Travere Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. R Squared Ltd bought a new stake in Travere Therapeutics during the fourth quarter worth about $53,000. CWM LLC boosted its holdings in shares of Travere Therapeutics by 158.5% in the 3rd quarter. CWM LLC now owns 4,999 shares of the company’s stock worth $70,000 after acquiring an additional 3,065 shares in the last quarter. Quarry LP bought a new stake in Travere Therapeutics during the 3rd quarter worth approximately $105,000. Forefront Analytics LLC grew its position in Travere Therapeutics by 10.2% during the 2nd quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock worth $109,000 after acquiring an additional 1,237 shares during the last quarter. Finally, Sei Investments Co. acquired a new stake in Travere Therapeutics during the 2nd quarter valued at $117,000.

Insider Buying and Selling at Travere Therapeutics

In other Travere Therapeutics news, SVP William E. Rote sold 2,437 shares of Travere Therapeutics stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $19.46, for a total transaction of $47,424.02. Following the completion of the transaction, the senior vice president now directly owns 83,170 shares of the company’s stock, valued at approximately $1,618,488.20. This trade represents a 2.85 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Roy D. Baynes sold 16,000 shares of the business’s stock in a transaction on Thursday, January 23rd. The shares were sold at an average price of $20.00, for a total transaction of $320,000.00. Following the completion of the sale, the director now owns 31,000 shares in the company, valued at $620,000. This represents a 34.04 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 62,143 shares of company stock valued at $1,167,512. 3.75% of the stock is currently owned by corporate insiders.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.